New CMS Mandate on Diabetes Harm Measures Impacting
Patients and Providers to Drive Outcomes and Health
Equity
BOSTON, April 18,
2024 /PRNewswire/ -- Glytec, whose industry leading
SaaS platform empowers collaborative diabetes management and
insulin dosing from the hospital to the home, announces a major
step forward in its advocacy and partnership efforts to drive
excellence in diabetes care and a commitment to enable hospitals
and providers to measure and improve outcomes for patients.
Recently, CMS proposed the addition of two new mandatory
electronic clinical quality measures (eCQMs) related to Severe
Hypoglycemia and Severe Hyperglycemia for the CY 2026 reporting
period. The proposed rule change issued on April 10, 2024, impacts hospitals through the
Hospital Inpatient Quality Reporting (IQR) program. These
measurements are published, used by various agencies and
organizations for reimbursement purposes, and provide market
guidance on hospital safety and quality. You can read more about
the proposed rule and access the full text on the CMS
website.[1]
Dr. Bruce Bode, co-founder of
Glytec and world-renowned diabetologist, who pioneered glucose
management protocols in hospitals noted, "Robby Booth and I founded Glytec to innovate
beyond the manual paper protocols used by hospitals, and over the
last 15 years we have developed industry-leading technology to
measure and improve outcomes in hospital diabetes care. We are
proud to align with industry experts, partners, clients, and CMS in
supporting measures to advance diabetes care, reduce health
inequities, and move beyond antiquated, paper-based solutions."
Glytec's advocacy effort, "Championing Change," has
partnered with industry trade groups and key opinion leaders to
advance our mission to revolutionize healthcare and health
economics by empowering clinicians through data and insights. These
efforts have produced the first ever FDA-cleared software to manage
insulin, are supported by 106 patents and over 100 clinical
publications, and now through collaboration with U.S. Congress,
Centers for Medicare and Medicaid Services (CMS), the U.S.
Department of Health and Human Services (HHS), and the White House,
we have taken another important step in helping to advance
reporting and care standards for patients across the nation.
Reacting to the recent CMS news, Dr. Greg Maynard, Chief Quality Officer at UC Davis
Medical Center, and nationally recognized expert in hospital
quality improvement noted, "Diabetes and glycemic control experts
have long advocated for standardized glycemic control measures, and
CMS's introduction of glycemic measures in 2023 was a pivotal step.
Making these measures mandatory will raise awareness and make
glycemic control and hypoglycemia rates transparent and available
to the public. Mandatory public reporting will provide an impetus
to improve diabetes and hyperglycemia care and serve as a
foundation for deeper analytics that hospitals will need to drive
improvements in care delivery."
The mandatory measures are related to glucose and diabetes
management, which have been significant challenges for the
healthcare industry. One-third of all hospitalized patients require
insulin therapy to regulate high blood sugar during their
stay.[2] More than 2 million patients each year
experience an adverse event in the hospital leading to
hypoglycemia, which according to the Agency for Healthcare Research
and Quality (AHRQ) costs the healthcare system over 8 billion dollars. Most patients impacted have
diabetes and are subject to a 3 times higher likelihood of
hospitalization, 2.6 times higher healthcare costs, and health
inequities including disproportionate outcomes due to racial and
ethnic minority status, low income, low education, and
age.[3]
Yet nearly one-third of hospitals have no glucose management
metrics, and 59 percent do not have an automated method of pulling
data on rates of hyperglycemia and
hypoglycemia.[4] Many hospitals still rely on
dated, manual methods for managing blood glucose and don't have
tools to measure and improve outcomes across their patient
populations, leaving them decades behind best practices and
tools.
"Our mission and solution are trusted by over 350
forward-thinking hospitals who have partnered to measurably improve
patient outcomes and clinical workflows, and to decrease hospital
stays, readmissions, and cost of care. While there is still work to
be done, we are proud to continue to be at the forefront of
advancing glucose and diabetes care along with our hospital
partners," said Dr. Jordan Messler, Chief Medical Officer of
Glytec.
Glytec's goal is simple: to ensure that every hospital has
FDA-approved tools to safely achieve diabetes excellence for their
patients and providers. Stay up to date on all the details about
the new quality reporting metrics and learn what you can do to
prepare at www.glytecsystems.com.
About Glytec
(Glytec, Boston,
Mass.) Glytec's industry leading SaaS platform, trusted
by 350+ hospitals, empowers collaborative diabetes management and
insulin dosing, improving patient outcomes, reducing
readmissions, and streamlining workflows while delivering a 6-8x
ROI. The first-ever FDA-cleared cloud-based insulin management
software is EMR-integrated, easy to set up, and validated by 106
patents and over 100 publications. The Glytec Glucommander®
solution, with clinical decision support, workflow alerts, patient
monitoring, at-risk patient identification, and AI-driven
analytics, is supported by a mission-driven team dedicated to
helping healthcare leaders, clinicians and patients promote health
equity and improve diabetes outcomes from hospital to home. We are
on a mission, join us.
For more information, follow
Glytec on X (@Glytec) and LinkedIn, or
visit www.glytecsystems.com.
Sources
-
https://www.cms.gov/newsroom/fact-sheets/fy-2025-hospital-inpatient-prospective-payment-system-ipps-and-long-term-care-hospital-prospective
- Umpierrez, et al. J of Clin Endo & Met. 87,
no. 3 (March 2002):
978–82. https://doi.org/10.1210/jcem.87.3.8341.
- Hill-Briggs, et al. Diabetes Care 2021;44(1):258–279.
https://doi.org/10.2337/dci20-0053.
- Cook, et al. End Pract. 16, no. 2 (March 2010):
219-30. https://doi.org/10.4158/EP09234.OR.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/glytec-announces-support-for-landmark-new-cms-measures-to-improve-diabetes-reporting-302121070.html
SOURCE Glytec